Annual report pursuant to Section 13 and 15(d)

Organization and Description of Business - Additional Information (Detail)

v2.4.1.9
Organization and Description of Business - Additional Information (Detail) (USD $)
0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Aug. 12, 2014
Sep. 30, 2014
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2014
Apr. 18, 2014
Mar. 17, 2014
Jun. 16, 2014
Organization And Nature Of Business [Line Items]                  
Long-term Investments     $ 4,160,000us-gaap_LongTermInvestments $ 0us-gaap_LongTermInvestments   $ 4,160,000us-gaap_LongTermInvestments   $ 250,000us-gaap_LongTermInvestments  
Equity Method Investment, Ownership Percentage               35.00%us-gaap_EquityMethodInvestmentOwnershipPercentage  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases 50,000us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases   3,218,000us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases            
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net 293,000us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet 293,000us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet              
Fair Value, Assets Measured on Recurring Basis, Change in Unrealized Gain (Loss) 293,000us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss                
Equity Method Investments, Fair Value Disclosure     4,160,000us-gaap_EquityMethodInvestmentsFairValueDisclosure     4,160,000us-gaap_EquityMethodInvestmentsFairValueDisclosure      
Payments to Acquire Short-term Investments     346,000us-gaap_PaymentsToAcquireShortTermInvestments 0us-gaap_PaymentsToAcquireShortTermInvestments 0us-gaap_PaymentsToAcquireShortTermInvestments        
CB Pharma Acquisitions Corp [Member]                  
Organization And Nature Of Business [Line Items]                  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases     2,675,000us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
           
Fair Value, Assets Measured on Recurring Basis, Change in Unrealized Gain (Loss)     1,200,000us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
           
Sale Of Stock Number Of Insider Shares Issued In Transaction   1,100,000cndo_SaleOfStockNumberOfInsiderSharesIssuedInTransaction
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
             
Stock Repurchased During Period, Shares   100,000us-gaap_StockRepurchasedDuringPeriodShares
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
             
Proceeds from Issuance Initial Public Offering           42,900,000us-gaap_ProceedsFromIssuanceInitialPublicOffering
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
     
Sale of Stock, Number of Shares Issued in Transaction           265,000us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
     
Sale of Stock, Price Per Share     $ 10.00us-gaap_SaleOfStockPricePerShare
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
    $ 10.00us-gaap_SaleOfStockPricePerShare
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
     
Exercise Price Of Warrants     11.50%cndo_ExercisePriceOfWarrants
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
           
Proceeds from Issuance of Private Placement           2,700,000us-gaap_ProceedsFromIssuanceOfPrivatePlacement
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
     
Business Combination, Step Acquisition, Equity Interest in Acquiree, Including Subsequent Acquisition, Percentage     23.00%us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
    23.00%us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
     
Equity Method Investments, Fair Value Disclosure     3,900,000us-gaap_EquityMethodInvestmentsFairValueDisclosure
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
    3,900,000us-gaap_EquityMethodInvestmentsFairValueDisclosure
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
     
Payments to Acquire Short-term Investments   25,000us-gaap_PaymentsToAcquireShortTermInvestments
/ invest_InvestmentIssuerAxis
= cndo_CbPharmaAcquisitionsCorpMember
             
Employee Stock Option [Member]                  
Organization And Nature Of Business [Line Items]                  
Payments to Acquire Short-term Investments             243,000us-gaap_PaymentsToAcquireShortTermInvestments
/ us-gaap_OptionIndexedToIssuersEquityEquityAxis
= us-gaap_EmployeeStockOptionMember
   
Nuro Pharma Inc [Member] | Bridge Loan [Member]                  
Organization And Nature Of Business [Line Items]                  
Loans Receivable Interest Rate                 8.00%cndo_LoansReceivableInterestRate
/ us-gaap_RelatedPartyTransactionAxis
= cndo_NuroPharmaIncMember
/ us-gaap_ShortTermDebtTypeAxis
= us-gaap_BridgeLoanMember
Financing Receivable, Recorded Investment, Current               $ 50,000us-gaap_FinancingReceivableRecordedInvestmentCurrent
/ us-gaap_RelatedPartyTransactionAxis
= cndo_NuroPharmaIncMember
/ us-gaap_ShortTermDebtTypeAxis
= us-gaap_BridgeLoanMember